10/20/21 7:07 PMNYSE : MRKCDC ACIP Unanimously Votes to Provisionally Recommend Merck’s VAXNEUVANCE™ (Pneumococcal 15-valent Conjugate Vaccine) in Series with PNEUMOVAX ® 23 (Pneumococcal Vaccine Polyvalent) as an Option for Pneumococcal Vaccination in Appropriate AdultsMerck, known as MSD outside the United States and Canada, today announced the U.S. Centers for Disease Control and Prevention’ s Advisory Committee on Immunization Practices unanimously voted in favor of updates to pneumococcal vaccination recommendations for adults 65 years and older, and for adults ages 19 to 64 with certain underlying medical conditions...RHEA-AInegative
10/20/21 8:00 AMNasdaq, NYSE : XLRN, MRKDarwin Global Urges Acceleron Shareholders Not to Tender Their Shares to MerckDarwin Global Management Limited, a long-term investor in the biotechnology and pharmaceutical sector and beneficial owner of 2,345,620 shares of common stock of Acceleron Pharma...RHEA-AIneutral
10/19/21 7:30 PMNYSE : MRKMerck Issues Voluntary Nationwide Recall of CUBICIN® (daptomycin for injection) 500 mg, Lot 934778, Due to Presence of Particulate Matter Identified as Glass ParticlesMerck, known as MSD outside the United States and Canada, is voluntarily recalling one lot of CUBICIN ® 500 mg for intravenous use, Lot 934778, Exp June 2022. Because treatment with CUBICIN is likely to be initiated at a hospital or other monitored healthcare setting, the recall is being conducted to the user level, including hospital and administering...RHEA-AIvery negative
10/18/21 11:54 AMNasdaq, NYSE : XLRN, MRKACCELERON PHARMA ALERT: Investors Should Contact Bragar Eagel & Squire, P.C. Over Tender Offer for XLRN SharesBragar Eagel& Squire, P.C., a nationally recognized stockholder rights law firm, has launched an investigation into whether the officers or directors of Acceleron Pharma Inc. breached their fiduciary duties or violated the federal securities laws in connection with the company’ s acquisition by Merck& Co., Inc.. On September 30, 2021, Acceleron announced that...RHEA-AIneutral
10/15/21 7:20 AMNYSE : MRKMerck and Eisai Receive Positive EU CHMP Opinions for KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) in Two Different Types of CancerMerck, known as MSD outside the United States and Canada, and Eisai today announced that the Committee for Medicinal...RHEA-AIvery positive
10/15/21 7:15 AMNYSE : MRKMerck Receives Positive CHMP Opinion for VAXNEUVANCE™ (Pneumococcal 15-valent Conjugate Vaccine) in Individuals 18 Years of Age and OlderMerck, known as MSD outside the United States and Canada, today announced that the European Medicines Agency’ s Committee for Medicinal Products for Human Use has recommended the approval of VAXNEUVANCE™ for active immunization for the prevention of invasive disease and pneumonia caused by Streptococcus pneumoniae in individuals 18 years of age and older.RHEA-AIneutral
10/13/21 3:30 PMNasdaq, NYSE : XLRN, MRKHolocene Advisors Believes Merck’s Proposed Offer of $180 Per Share for Acceleron Significantly Undervalues CompanyHolocene Advisors, LP, a fundamental investment management firm and significant shareholder of Acceleron Pharma Inc., today announced that it does not intend to tender its shares into Merck& Co.’ s proposed $180 per share offer for the Company announced on September 30, 2021. While Merck ultimately could be an attractive partner for Acceleron, we believe its...RHEA-AIneutral
10/13/21 2:45 PMNYSE : MRKfda approvalFDA Approves Merck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy, With or Without Bevacizumab, as Treatment for Patients With Persistent, Recurrent or Metastatic Cervical Cancer Whose Tumors Express PD-L1 (CPS ≥1)Merck, known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration has approved KEYTRUDA, Merck’ s anti-PD-1 therapy, in combination with chemotherapy, with or without bevacizumab, for the treatment of patients with persistent, recurrent or metastatic cervical cancer whose tumors express PD-L1 as determined by...RHEA-AIneutral
10/12/21 6:45 AMNYSE, Nasdaq : MRK, XLRNacquisitionMerck Begins Tender Offer to Acquire Acceleron Pharma Inc.Merck, known as MSD outside the United States and Canada, is commencing today, through a subsidiary, a cash tender offer to purchase all outstanding shares of common stock of Acceleron Pharma Inc.. Additionally, Acceleron will file with the SEC a solicitation/recommendation statement on Schedule 14 D-9 that includes the recommendation of the Acceleron board...RHEA-AIneutral
10/11/21 7:30 AMNYSE : OGN, MRKOrganon Receives FDA Clearance for Technological Updates to the Jada® System, a Medical Device Intended to Control Postpartum HemorrhageOrganon, a global women’ s health company, today announced clearance by the U.S. Food and Drug Administration of the Special 510 for technological updates to the Jada ® System, intended to provide control and treatment of abnormal postpartum uterine bleeding or hemorrhage when conservative management is warranted. The incidence of postpartum hemorrhage...RHEA-AIneutral
